News
AOP Orphan Pharmaceuticals presents latest analysis on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the prestigious American Society of Hematology (ASH) 2021 Annual Meeting
14. 12. 2021BESREMi® (Ropeginterferon alfa-2b) approved by the US FDA
15. 11. 2021New Approaches for Fostering Rare Disease Research
18. 10. 2021
From the Concept to the Drug
AOP Orphan team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering
Partnering is of key importance for AOP Orphan. It allows further developing AOP Orphan’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe.
Join AOP Orphan
AOP Orphan team develops and investigates therapy options for patients with rare diseases – commitment and appreciation are the essence of our cooperative work.